A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.
Once- and thrice-daily treatment with aminoglycosides appear to be equally effective for reducing pulmonary exacerbations in cystic fibrosis.
The FDA has accepted for priority review the NDA for elexacaftor, tezacaftor and ivacaftor triple combination regimen for patients with cystic fibrosis.
The NDA for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA.
Ivacaftor use was linked to reductions in P. aeruginosa rates, prevalence of S. aureus, Aspergillus species.
Treatment with palivizumab was not associated with improved long-term outcomes in children with cystic fibrosis.
Ivacaftor is safe and effective in patients with cystic fibrosis who have severe lung disease and non-G551D gating mutations.
Treatment with azithromycin is associated with short-term, but not long-term, changes in lung function in children with cystic fibrosis.
The FDA has granted Orphan Drug designation to AR-501, an investigational treatment for chronic bacterial lung infections in patients with cystic fibrosis.
Combinations of ibuprofen with aztreonam and ceftazidime display synergistic antimicrobial activity against drug-resistant Pseudomonas aeruginosa isolates in vitro.
